Skip to main content
SpringerLink
Log in

Combination Therapy In Dyslipidemia

  • Book
  • © 2015

Overview

Editors:
  1. Maciej Banach

    1. Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Lodz, Poland

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Addresses a gap left by the latest dyslipidemia management guidelines

  • Current and comprehensive discussion of options for combination therapy of dyslipidemia

  • Contributions from an internationally acclaimed panel of expert lipidologists

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (17 chapters)

  1. Front Matter

    Pages i-viii
    Download chapter PDF

  2. Use of Combination Statin and Bile Acid Sequestrant Therapy to Treat Dyslipidemia

    • Peter P. Toth, Dragana Nikolic, Manfredi Rizz, Jacek Rysz, Maciej Banach
    Pages 1-10

  3. Statins and Fibrates: Should They Be Recommended?

    • Piotr ChruÅ›ciel, Dimitri P. Mikhailidis, Peter P. Toth, Jacek Rysz, Maciej Banach
    Pages 11-23

  4. Statins and Ezetimibe

    • Ulrich Laufs
    Pages 25-36

  5. Statins and Niacin: The End of Residual Risk Therapy?

    • Aris P. Agouridis, Dimitri P. Mikhailidis
    Pages 37-43

  6. The Role of Omega-3 Fatty Acids in Dyslipidemias

    • Eric J. Brandt, Michael H. Davidson
    Pages 45-64

  7. Statins and CETP Inhibitors: Anacetrapib and Evacetrapib: The Last Hope?

    • Stephen J. Nicholls
    Pages 65-71

  8. Statins and Mipomersen: Mechanisms of Action and Patient Tolerability

    • Jing Pang, Dick C. Chan, Gerald F. Watts
    Pages 73-86

  9. Statins and Lomitapide: A Suitable Response for Homozygous Familial Hypercholesterolemia?

    • Angela Pirillo, Alberico Luigi Catapano
    Pages 87-97

  10. Statins and PCSK9 Inhibitors: Defining the Correct Patients

    • Michel Farnier
    Pages 99-117

  11. Other Possible Drug Combinations for Dyslipidemia

    • Karam Kostner
    Pages 119-125

  12. Statins and Nutraceuticals/Functional Food: Could They Be Combined?

    • Arrigo F. G. Cicero, Alessandro Colletti
    Pages 127-142

  13. Lipid-Lowering Therapy and Apheresis: Indications and Outcomes

    • Patrick M. Moriarty, Audrey E. McCalley
    Pages 143-152

  14. Combination of Lipid-Lowering Agents with Antihypertensive Drugs: A Joint Fight Against the Two Most Important Risk Factors?

    • Yanglu Zhao, Nathan D. Wong
    Pages 153-163

  15. The Cardiovascular Polypill in the Prevention of Cardiovascular Disease

    • Melvin Lafeber
    Pages 165-177

  16. Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom?

    • Dragana Nikolic, Niki Katsiki, Peter P. Toth, Maciej Banach, Khalid Al-Waili, Khalid Al-Rasadi et al.
    Pages 179-190

  17. Drug Evaluation: Olmesartan Medoxomil + Rosuvastatin for the Treatment of Dyslipidemia and Concomitant Risk Factors: A Chance for Better Compliance?

    • Joanna Gozdzikiewicz-Lapinska, Jolanta Malyszko
    Pages 191-200

  18. Conclusions and Take Home Message

    • Maciej Banach
    Pages 201-205
Back to top

Keywords

About this book

Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia and includes discussion of future therapies that are currently in late stages of clinical evaluation.

Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia.

Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on therapy with different agents modulating the different lipid fractions in the blood, e.g. bile acid sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP) and the emerging proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. There is additional discussion of the role of non-drug therapy options such as nutraceuticals, functional foods and lipoprotein apheresis. The book also discusses the combination of antihypertensive drugs with lipid-lowering drugs in the management of cardiovascular risk in patents with dyslipidemia.

Editors and Affiliations

  • Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Lodz, Poland

    Maciej Banach

Bibliographic Information

  • Book Title: Combination Therapy In Dyslipidemia

  • Editors: Maciej Banach

  • DOI: https://doi.org/10.1007/978-3-319-20433-8

  • Publisher: Adis Cham

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Springer International Publishing Switzerland 2015

  • Hardcover ISBN: 978-3-319-20432-1Published: 10 July 2015

  • Softcover ISBN: 978-3-319-36721-7Published: 15 October 2016

  • eBook ISBN: 978-3-319-20433-8Published: 31 July 2015

  • Edition Number: 1

  • Number of Pages: VIII, 205

  • Number of Illustrations: 7 b/w illustrations, 15 illustrations in colour

  • Topics: Cardiology, Pharmacotherapy, Pharmacology/Toxicology

Publish with us

Policies and ethics

Back to top

Search

Navigation